World Malaria Report 2024 (World Health Organization, 2024); www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
Aly, A. S., Vaughan, A. M. & Kappe, S. H. Malaria parasite development in the mosquito and infection of the mammalian host. Annu. Rev. Microbiol. 63, 195–221 (2009).
Yamauchi, L. M., Coppi, A., Snounou, G. & Sinnis, P. Plasmodium sporozoites trickle out of the injection site. Cell Microbiol. 9, 1215–1222 (2007).
Potocnjak, P., Yoshida, N., Nussenzweig, R. S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151, 1504–1513 (1980).
Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593–599 (1984).
World Health Organization. Malaria vaccines: WHO position paper. Wkly Epidemiol. Rec. 99, 225–248 (2024).
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533–544 (2024).
Bousema, T., Okell, L., Felger, I. & Drakeley, C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat. Rev. Microbiol. 12, 833–840 (2014).
Juraska, M. et al. Genotypic analysis of RTS,S/AS01(E) malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. Lancet Infect. Dis. 24, 1025–1036 (2024).
Bojang, K. A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927–1934 (2001).
Polhemus, M. E. et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 4, e6465 (2009).
Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408–416 (2018).
Gaudinski, M. R. et al. A monoclonal antibody for malaria prevention. N. Engl. J. Med. 385, 803–814 (2021).
Wang, L. T., Idris, A. H., Kisalu, N. K., Crompton, P. D. & Seder, R. A. Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention. Nat. Immunol. 25, 1530–1545 (2024).
Kayentao, K. et al. Safety and efficacy of a monoclonal antibody against malaria in Mali. N. Engl. J. Med. 387, 1833–1842 (2022).
Bejon, P. et al. Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar. J. 5, 104 (2006).
Wongsrichanalai, C., Barcus, M. J., Muth, S., Sutamihardja, A. & Wernsdorfer, W. H. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am. J. Trop. Med. Hyg. 77, 119–127 (2007).
Seilie, A. M. et al. Beyond blood smears: qualification of plasmodium 18S rRNA as a biomarker for controlled human malaria infections. Am. J. Trop. Med. Hyg. 100, 1466–1476 (2019).
Hergott, D. E. B. et al. Assessing the daily natural history of asymptomatic Plasmodium infections in adults and older children in Katakwi, Uganda: a longitudinal cohort study. Lancet Microbe 5, e72–e80 (2024).
Matsubara, J., Chang, M., Seilie, A. M. & Murphy, S. C. Flow cytometric sorting of infected erythrocytes demonstrates reliable detection of individual ring-stage Plasmodium falciparum parasites by plasmodium 18S rRNA reverse transcription polymerase chain reaction. Am. J. Trop. Med. Hyg. 106, 1653–1659 (2022).
Hanron, A. E. et al. Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs. Malar. J. 16, 208 (2017).
Kayentao, K. et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N. Engl. J. Med. 390, 1549–1559 (2024).
Chavtur, C. et al. Plasmodium 18S ribosomal RNA biomarker clearance after Food and Drug Administration-approved antimalarial treatment in controlled human malaria infection trials. Open Forum Infect. Dis. 10, ofad202 (2023).
Andolina, C. et al. Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. Lancet Infect. Dis. 21, 1568–1578 (2021).
Schneider, P. et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am. J. Trop. Med. Hyg. 76, 470–474 (2007).
Sutherland, C. J. et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med. 2, e92 (2005).
Sawa, P. et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J. Infect. Dis. 207, 1637–1645 (2013).
Mahamar, A. et al. Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali. Lancet Microbe 5, 633–644 (2024).
Duffey, M. et al. Combating antimicrobial resistance in malaria, HIV and tuberculosis. Nat. Rev. Drug Discov. 23, 461–479 (2024).
Dhorda, M. et al. Artemisinin-resistant malaria in Africa demands urgent action. Science 385, 252–254 (2024).
McCreary, E. K. et al. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. Ann. Intern. Med. 175, 1707–1715 (2022).
Crispino, P. et al. Use of monoclonal antibodies in pregnant women infected by COVID-19: a case series. Microorganisms 11, 1953 (2023).
Folkman, R., Blennow, O., Tovatt, T., Pettersson, K. & Nowak, P. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infection 51, 261–263 (2023).
Levey, N. H. et al. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic. Am. J. Obstet. Gynecol. MFM 4, 100673 (2022).
Pham-Huy, A., Top, K. A., Constantinescu, C., Seow, C. H. & El-Chaar, D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 193, E1129–E1136 (2021).
Figueroa-Romero, A., Pons-Duran, C. & Gonzalez, R. Drugs for intermittent preventive treatment of malaria in pregnancy: current knowledge and way forward. Trop. Med. Infect. Dis. 7, 152 (2022).
van der Boor, S. C. et al. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect. Dis. 22, 1596–1605 (2022).
Duffy, P. E. Transmission-blocking vaccines: harnessing herd immunity for malaria elimination. Expert Rev. Vaccines 20, 185–198 (2021).
Copeland, N. K. et al. Phase 2b clinical study evaluating efficacy of RTS,S/AS01E in Plasmodium falciparum-exposed Kenyan adults treated with antimalarial chemopreventive drugs. Preprint at medRxiv https://doi.org/10.1101/2025.01.10.25320353 (2025).
Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377–389 (2022).
Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27, 1636–1645 (2021).
Murphy, S. C. et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am. J. Trop. Med. Hyg. 86, 383–394 (2012).
Hergott, D. E. B. et al. Feasibility of community at-home dried blood spot collection combined with pooled reverse transcription PCR as a viable and convenient method for malaria epidemiology studies. Malar. J. 21, 221 (2022).
Chang, M., Johnston, S., Seilie, A. M., Hergott, D. & Murphy, S. C. Application of dried blood spot sample pooling strategies for Plasmodium 18S rRNA biomarker testing to facilitate identification of infected persons in large-scale epidemiological studies. Malar. J. 20, 391 (2021).
Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733–744.e8 (2020).
Wu, R. L. et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N. Engl. J. Med. 387, 397–407 (2022).
Andrade, C. M. et al. Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season. Nat. Med. 26, 1929–1940 (2020).
Diallo, D. A. et al. Community permission for medical research in developing countries. Clin. Infect. Dis. 41, 255–259 (2005).
Murphy, S. C., Daza, G., Chang, M. & Coombs, R. Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J. Clin. Microbiol. 50, 4128–4130 (2012).
MalariaGEN. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples. Wellcome Open Res. 8, 22 (2023).
Miles, A. et al. cggh/scikit-allel: v1.3.13. Zenodo https://doi.org/10.5281/zenodo.13772087 (2024).
LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: a malaria case study. Mol. Ecol. Resour. 22, 2285–2303 (2022).
Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
Wickham, H. stringr: simple, consistent wrappers for common string operations. R package version 1.5.1 https://cran.r-project.org/web/packages/stringr/index.html (2023).
